onr:"swepub:oai:openarchive.ki.se:10616/46281"
Search: onr:"swepub:oai:openarchive.ki.se:10616/46281" > Helicobacter pylori...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Doorakkers, Eva (author)
Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population
- Article/chapterEnglish2018
Publisher, publication year, extent ...
- 2018-01-30
- Stockholm :Karolinska Institutet, Dept of Molecular Medicine and Surgery,2018
- electronicrdacarrier
Numbers
- LIBRIS-ID:oai:openarchive.ki.se:10616/46281
- ISSN:0017-5749
- 10616/46281hdl
- http://hdl.handle.net/10616/46281URI
- https://doi.org/10.1136/gutjnl-2017-315363DOI
- http://kipublications.ki.se/Default.aspx?queryparsed=id:139707112URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- OBJECTIVE: Gastric infection with Helicobacter pylori is a strong risk factor for non-cardia gastric adenocarcinoma. The aim of this study was to assess whether the risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma decreases after eradication treatment for H. pylori in a Western population. DESIGN: This was a nationwide, population-based cohort study in Sweden in 2005-2012. Data from the Swedish Prescribed Drug Registry provided information on H. pylori eradication treatment, whereas information concerning newly developed gastric adenocarcinoma was retrieved from the Swedish Cancer Registry. The risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in individuals who had received H. pylori eradication treatment was compared with the background population of the corresponding age, sex and calendar year distribution, yielding standardised incidence ratios (SIRs) with 95% CIs. RESULTS: During the follow-up of 95 176 individuals who had received eradication treatment (351 018 person-years at risk), 75 (0.1%) developed gastric adenocarcinoma and 69 (0.1%) developed non-cardia gastric adenocarcinoma. The risk of gastric adenocarcinoma decreased over time after eradication treatment to levels below that of the corresponding background population. The SIRs were 8.65 (95% CI 6.37 to 11.46) for 1-3 years, 2.02 (95% CI 1.25 to 3.09) for 3-5 years and 0.31 (95% CI 0.11 to 0.67) for 5-7.5 years after eradication treatment. When restricted to non-cardia adenocarcinoma, the corresponding SIRs were 10.74 (95% CI 7.77 to 14.46), 2.67 (95% CI 1.63 to 4.13) and 0.43 (95% CI 0.16 to 0.93). CONCLUSION: Eradication treatment for H. pylori seems to counteract the development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this Western population.
Added entries (persons, corporate bodies, meetings, titles ...)
- Lagergren, JesperKarolinska Institutet (author)
- Engstrand, LarsKarolinska Institutet (author)
- Brusselaers, NeleKarolinska Institutet (author)
- Karolinska Institutet
- Karolinska Institutet
- Karolinska Institutet (creator_code:org_t)
Related titles
- In:GutStockholm : Karolinska Institutet, Dept of Molecular Medicine and Surgery0017-57491468-3288
Internet link
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Doorakkers, Eva
- Lagergren, Jespe ...
- Engstrand, Lars
- Brusselaers, Nel ...
- Articles in the publication
- Gut
- By the university
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
